Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

Tumour growth requires accompanying expansion of the host vasculature, with tumour progression often correlated with vascular density. Vascular endothelial growth factor (VEGF) is the best-characterized inducer of tumour angiogenesis. We report that VEGF dynamically regulates tumour endothelial expression of Delta-like ligand 4 (Dll4), which was previously shown to be absolutely required for normal embryonic vascular development. To define Dll4 function in tumour angiogenesis, we manipulated this pathway in murine tumour models using several approaches. Here we show that blockade resulted in markedly increased tumour vascularity, associated with enhanced angiogenic sprouting and branching. Paradoxically, this increased vascularity was non-productive—as shown by poor perfusion and increased hypoxia, and most importantly, by decreased tumour growth—even for tumours resistant to anti-VEGF therapy. Thus, VEGF-induced Dll4 acts as a negative regulator of tumour angiogenesis; its blockade results in a striking uncoupling of tumour growth from vessel density, presenting a novel therapeutic approach even for tumours resistant to anti-VEGF therapies.

[1]  J. Hsieh,et al.  A secreted Delta1‐Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling , 2002, Journal of neuroscience research.

[2]  J. Kitajewski,et al.  Notch function in the vasculature: insights from zebrafish, mouse and man , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[3]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[4]  Tasuku Honjo,et al.  Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. , 2004, Genes & development.

[5]  Janet Rossant,et al.  Dosage-sensitive requirement for mouse Dll4 in artery development. , 2004, Genes & development.

[6]  Christopher C W Hughes,et al.  Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. , 2002, Microvascular research.

[7]  T. Gridley Notch signaling during vascular development , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Augustin,et al.  Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. , 2006, Cancer research.

[9]  R. Kerbel,et al.  Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches , 2004, Cancer and Metastasis Reviews.

[10]  M. Herlyn,et al.  Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1 , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[12]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R Bicknell,et al.  Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. , 2001, Differentiation; research in biological diversity.

[14]  J. Folkman,et al.  The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.

[15]  D. McDonald,et al.  Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. , 1996, The American journal of physiology.

[16]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[17]  G. Yancopoulos,et al.  VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets. , 2005, Cold Spring Harbor symposia on quantitative biology.

[18]  M. Bevan,et al.  The Nrarp gene encodes an ankyrin-repeat protein that is transcriptionally regulated by the notch signaling pathway. , 2001, Developmental biology.

[19]  S. Artavanis-Tsakonas,et al.  Notch signaling: cell fate control and signal integration in development. , 1999, Science.

[20]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[21]  Larry Kedes,et al.  HES and HERP families: Multiple effectors of the notch signaling pathway , 2003, Journal of cellular physiology.

[22]  A. Karsan The role of notch in modeling and maintaining the vasculature. , 2005, Canadian journal of physiology and pharmacology.

[23]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[24]  M Ancukiewicz,et al.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.

[25]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[26]  Gavin Thurston,et al.  Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Niehrs,et al.  Nrarp is a novel intracellular component of the Notch signaling pathway. , 2001, Genes & development.

[28]  A. Sandler,et al.  First-line treatment for advanced non-small-cell lung cancer. , 2005, Oncology.

[29]  Rakesh K Jain,et al.  Antiangiogenic therapy for cancer: current and emerging concepts. , 2005, Oncology.

[30]  R. Jain Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. , 2002, Seminars in oncology.

[31]  Adrian L Harris,et al.  Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. , 2005, Cancer research.

[32]  N. Ferrara Vascular endothelial growth factor as a target for anticancer therapy. , 2004, The oncologist.

[33]  J. Kitajewski,et al.  Notch Signaling in Primary Endothelial Cells , 2003, Annals of the New York Academy of Sciences.